医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IONTAS Signs Collaboration Agreement With LG Chem, Ltd. to Identify Therapeutic Oncology Leads

2018年06月05日 PM06:54
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England & SEOUL, South Korea

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.

Dr Neil Butt, CBO of IONTAS, said: “This new agreement marks IONTAS’ expansion into the Asian market, and we are delighted to have been selected by LG Chem, Ltd., after a rigorous diligence process. The application of our proprietary technologies will assist LG Chem, Ltd. in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”

Dr Myung Jin Kim, Executive Vice President / R&D Leader, Life Sciences R&D of LG Chem, Ltd., said: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”

Dr Neil Butt and Dr Mike Dyson, CTO of IONTAS, will attend the 2018 BIO International Convention (Boston, MA) from June 4 – 7 and Dr John McCafferty, CEO and Founder of IONTAS, will be at Antibody Engineering and Therapeutics Europe (Amsterdam, NL) from 5 – 7 June.

For further information, please visit https://www.iontas.co.uk/technologies/

ENDS

For a high-resolution image please contact lorna.cuddon@zymecommunications.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180605005820/en/

CONTACT

IONTAS Ltd
Neil Butt, Chief Business Officer
Tel: +44
1223 750801
bd@iontas.co.uk
or
Zyme
Communications

Lorna Cuddon
Tel: +44 (0)1223 968 920
lorna.cuddon@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc